CRESCENT BIOPHARMA INC (CBIO) Stock Overview
USA - NASDAQ:CBIO - KYG2545C1042 - Common Stock
CBIO Key Statistics, Chart & Performance
The current stock price of CBIO is 11.35 USD. In the past month the price decreased by -9.13%.
CBIO Latest News, Press Relases and Analysis
CBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.77 | 407.19B | ||
| AMGN | AMGEN INC | 13.3 | 156.19B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 145.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 104.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.85B | ||
| ARGX | ARGENX SE - ADR | 85.97 | 48.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.17 | 35.16B | ||
| INSM | INSMED INC | N/A | 34.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 23.23B | ||
| BIIB | BIOGEN INC | 9.15 | 21.49B |
Related stock screener links
About CBIO
Company Profile
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Company Info
CRESCENT BIOPHARMA INC
300 Fifth Avenue
Waltham MASSACHUSETTS 94080 US
CEO: Nassim Usman
Employees: 4
Phone: 16174305595
CRESCENT BIOPHARMA INC / CBIO FAQ
What is the stock price of CRESCENT BIOPHARMA INC today?
The current stock price of CBIO is 11.35 USD. The price decreased by -7.5% in the last trading session.
What is the ticker symbol for CRESCENT BIOPHARMA INC stock?
The exchange symbol of CRESCENT BIOPHARMA INC is CBIO and it is listed on the Nasdaq exchange.
On which exchange is CBIO stock listed?
CBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CRESCENT BIOPHARMA INC stock?
13 analysts have analysed CBIO and the average price target is 26.01 USD. This implies a price increase of 129.16% is expected in the next year compared to the current price of 11.35. Check the CRESCENT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CRESCENT BIOPHARMA INC worth?
CRESCENT BIOPHARMA INC (CBIO) has a market capitalization of 157.65M USD. This makes CBIO a Micro Cap stock.
How many employees does CRESCENT BIOPHARMA INC have?
CRESCENT BIOPHARMA INC (CBIO) currently has 4 employees.
What are the support and resistance levels for CRESCENT BIOPHARMA INC (CBIO) stock?
CRESCENT BIOPHARMA INC (CBIO) has a support level at 11 and a resistance level at 12.28. Check the full technical report for a detailed analysis of CBIO support and resistance levels.
Should I buy CRESCENT BIOPHARMA INC (CBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CBIO, evaluating the profitability, health, valuation and growth aspects
- CRESCENT BIOPHARMA INC (CBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CRESCENT BIOPHARMA INC (CBIO) Sales and EPS estimates to see what analysts future expectations are.
- CRESCENT BIOPHARMA INC (CBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CRESCENT BIOPHARMA INC (CBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CRESCENT BIOPHARMA INC (CBIO) Stock Chart to make your own analysis
- CRESCENT BIOPHARMA INC (CBIO) Latest news and press-releases to stay up to date.
Does CRESCENT BIOPHARMA INC (CBIO) stock pay dividends?
CBIO does not pay a dividend.
When does CRESCENT BIOPHARMA INC (CBIO) report earnings?
CRESCENT BIOPHARMA INC (CBIO) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of CRESCENT BIOPHARMA INC (CBIO)?
CRESCENT BIOPHARMA INC (CBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
What is the Short Interest ratio of CRESCENT BIOPHARMA INC (CBIO) stock?
The outstanding short interest for CRESCENT BIOPHARMA INC (CBIO) is 2.17% of its float. Check the ownership tab for more information on the CBIO short interest.
CBIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CBIO.
CBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CBIO. While CBIO seems to be doing ok healthwise, there are quite some concerns on its profitability.
CBIO Financial Highlights
Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| Debt/Equity | 0 |
CBIO Forecast & Estimates
13 analysts have analysed CBIO and the average price target is 26.01 USD. This implies a price increase of 129.16% is expected in the next year compared to the current price of 11.35.